All In Biotech

Drug Trial Radar · NCT06506461

Gene Editing For Sickle Cell Disease

St. Jude Autologous Genome Edited Stem Cells For Sickle Cell Disease-1

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Dec 2029

Study completion Dec 2032

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 24 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD. Secondary Objective * To assess the efficacy autologous infusion of CRISPR/Cas9 genome-edited CD34+ HSPCs into patients with severe SCD.

Conditions

  • Sickle Cell Disease

Interventions

  • PlerixaforDrug

    Given Subcutaneous (under the skin)

  • BusulfanDrug

    Given Intravenous (IV)

  • Gene-modified CD34+ cellsBiological

    Given Intravenous (IV)

  • MotixafortideDrug

    Given Subcutaneous (under the skin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of neutrophil engraftment by day +42 after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 42 days of the cellular product infusion
  2. Incidence of platelet engraftment by day +60 after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 60 days of the cellular product infusion
  3. Sustenance of multi-lineage engraftment and polyclonal hematopoiesis as measured by counts of different clones of myeloid cells, T cells, B cells, and NK cells at 1 year after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 1 year of the cellular product infusion
  4. Frequency of off-target editing after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 3 years of the cellular product infusion
  5. Occurrence of secondary graft failure, clonal hematopoiesis, MDS, or AMLTime frame: Within 3 years of the cellular product infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.